Press Release | July 24, 2024
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
Read More
News | July 22, 2024
Vittoria Biotherapeutics Announces Peer-Reviewed Publication in Science Immunology
Read More
Press Release | July 10, 2024
Skyhawk Therapeutics Announces Positive Topline Results of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction
Read More
Press Release | July 9, 2024
Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
Read More
Press Release | June 27, 2024
« Back Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
Read More
Press Release | June 20, 2024
āshibio Raises $40M in Seed and Series A Financing to Advance Therapies for Bone and Connective Tissue Disorders
Read More
Press Release | May 28, 2024
Affini-T Therapeutics Announces First Patient Dosed in KRAS G12V Phase 1 Program and Presentation of Trial-in-Progress Poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Read More
Press Release | April 2, 2024
Freenome Announces Topline Results for PREEMPT CRC® to Validate the First Version of its Blood-Based Test for the Early Detection of Colorectal Cancer
Read More
News | March 25, 2024
Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million
Read More
News | February 21, 2024
Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases
Read More
Press Release | February 15, 2024
Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection
Read More
Press Release | February 8, 2024
Metagenomi Announces Pricing of Initial Public Offering
Read More
Press Release | February 4, 2024
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Read More
